Future Potential : The robust pipeline of increasingly effective agents, combined with emerging oral formulations and potential cost reduction strategies, suggests that current limitations may be surmountable with continued innovation and policy development
Metformin The main goal in type 1 diabetes management is to try and minimize the amount of insulin that might be required, says Trence
Christian Wber: has received honoraria consultancy/speaking from Apomedica, Curelator, Eli Lilly, Grnenthal, Hermes, Lundbeck, Novartis, Pfizer, Ratiopharm/Teva, and Stada
Will You Regain Weight After GLP-1 Medications
The three major hurdles that prevent faster and vast progress such as less sustainable behavior change, medication side effects, and medication cost
Why claims data alone cant explain real-world GLP-1 outcomes As adoption accelerates, pharmaceutical companies are racing to innovate through new formulations, delivery options, and combination approaches that improve tolerability and long-term outcomes
